Orthofix Medical Inc. (NASDAQ:OFIX) CEO Sells $157,739.42 in Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CEO Massimo Calafiore sold 9,203 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $17.14, for a total transaction of $157,739.42. Following the completion of the transaction, the chief executive officer now directly owns 124,151 shares in the company, valued at approximately $2,127,948.14. The trade was a 6.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Massimo Calafiore also recently made the following trade(s):

• On Friday, January 10th, Massimo Calafiore sold 10,078 shares of Orthofix Medical stock. The stock was sold at an average price of $16.83, for a total transaction of $169,612.74.

Orthofix Medical Stock Down 0.1 %

Shares of OFIX stock opened at $17.93 on Friday. The company has a market capitalization of $685.11 million, a price-to-earnings ratio of -5.73 and a beta of 1.10. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11. The company’s fifty day moving average price is $18.15 and its 200-day moving average price is $16.76. Orthofix Medical Inc. has a one year low of $12.08 and a one year high of $20.73.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on OFIX. Stifel Nicolaus upgraded Orthofix Medical from a “hold” rating to a “buy” rating and upped their price objective for the stock from $18.00 to $24.00 in a research note on Friday, November 8th. Roth Mkm restated a “buy” rating and issued a $22.00 price target (up previously from $20.00) on shares of Orthofix Medical in a research report on Friday, November 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.00.

Hedge Funds Weigh In On Orthofix Medical

Several large investors have recently made changes to their positions in OFIX. Paradigm Capital Management Inc. NY raised its stake in Orthofix Medical by 31.3% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 2,556,100 shares of the medical device company’s stock valued at $33,894,000 after purchasing an additional 609,137 shares during the period. Engine Capital Management LP grew its holdings in Orthofix Medical by 11.0% during the 2nd quarter. Engine Capital Management LP now owns 3,368,665 shares of the medical device company’s stock valued at $44,668,000 after buying an additional 333,364 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Orthofix Medical during the second quarter valued at approximately $2,193,000. HighVista Strategies LLC purchased a new position in shares of Orthofix Medical in the third quarter worth $1,689,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Orthofix Medical by 480.7% during the third quarter. JPMorgan Chase & Co. now owns 84,379 shares of the medical device company’s stock worth $1,318,000 after acquiring an additional 69,848 shares during the last quarter. 89.76% of the stock is currently owned by hedge funds and other institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.